AVA. V. Voropayeva

A. V. Voropayeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. V. Voropayeva has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence and genotypic distribution of high-risk human papilloma virus in Gomel region: Screening results of 11,382 women over 2018–2023

    by V. P. Lohinava, N. I. Shevchenko, A. V. Voropayeva, E. L. Gasich, О. П. Логинова

    INTRODUCTION. High-risk human papillomavirus (hrHPV) is a proven etiological factor in prevalence of cervical cancer. Screening with HPV genotyping in women and identifying significant regional virus genotypes is vital for implementation of HPV immunisation programmes.AIM. This study aimed to examine the prevalence, spectrum, and regional characteristics of hrHPV in women from different districts of Gomel region in 2018–2023, prior to the mass vaccination programme in the Republic of Belarus.MATERIALS AND METHODS. A total of 11,382 women from Gomel region and the city of Gomel aged 18 to 79 years were examined in 2018–2023. Biomaterial samples (endocervical scrapings) were taken from each study participant for subsequent molecular genetic analysis using polymerase chain reaction.RESULTS. A total of 14 different HPV genotypes have been detected. The incidence of hrHPV was 9% in the overall population and 9.7% in women of reproductive age. High hrHPV incidence was noted in women of early reproductive age: group of 18–24 years — 18.8% (95% CI 16.8–20.9), 25–29 years — 12.1% (95% CI 10.3–14.1), and 30–34 years — 9.2% (95% CI 7.8–10.7). A single HPV genotype was detected most frequently (78.6%); a combination of two HPV genotypes was detected in 86 patients (14.5%); ≥3 genotypes — in 41 patients (6.9%). The most common genotypes were 16 (52.2%), 18 (15.1%), 51 (18.9%), 56 (9.8%), and 31 (9.7%) HPV. Groups α9 (16 and 31 genotypes), α7 (18 genotype), α5 (51 genotype), and α6 (56 genotype) most frequently caused hrHPV infection in women. A change has been found in the structure of dominant hrHPV genotypes in Gomel region over the past 10 years.CONCLUSION. A high hrHPV prevalence has been established among women of reproductive age in Gomel region. Data on HPV genomic diversity in the region are essential for molecular epidemiological surveillance and will help assess the effectiveness of the Republican HPV immunisation programme launched in 2025.

  • Open Access

    Risk of developing cervical dysplasia: relationship with Human Papillomavirus Viral Cancer Risk and age

    by V. P. Lohinava, N. I. Shevchenko, A. V. Voropayeva, E. L. Gasich, I. V. Veyalkin, О. П. Логинова

    Objective. To assess the risk of developing cervical dysplasia depending on the type of human papillomavirus (HPV) and the age of women (on the case of women from Gomel region). Materials and methods. Cytological examination and testing for HPV of Viral Cancer Risk (VCR) were carried out from 2018 to 2023 using the Abbott RealTime hrHPV (USA) kit on the Abbott m2000sp device. This test separately detects HPV 16, HPV 18 and a pool of 12 additional HPV hrHPV types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). Material — scrapes from the cervical canal. 11382 women from Gomel region were examined. Results . According to the results of the molecular genetic study, the infection rate of HPV VCR in women of Gomel region was 8.97% (n=1022). A tendency for the highest infection rate was noted in younger women. Thus, the highest number of HPV-positive samples was detected in the groups of 18-24 years old (n=276), 25-29 years old (n=156), 30-34 years old (n = 154). It was found that the relative risk (RR) of developing high-grade dysplasia in case of infection with HPV VCR was significantly higher in women of the age groups of 25-29 years old (RR — 66.3 (95% confidence interval (CI) 15.58; 281.7)), 35-39 years old (RR 35.4 (95% CI 13.05; 95.79)) and 18-24 years old (RR 18.5 (95% CI 5.31; 64.46)). 711 (6.2%) women with a high probability of developing cervical dysplasia were identified. A high risk of developing dysplasia was noted in cases of infection with type 16 and/or type 18 of the virus, as well as for women aged 18-34 infected with other genotypes of HPV VCR. Conclusion. Information on age and infection ith various genotypes of HPV VCR may be very useful for formation of risk groups of development of cervical dysplasia and effective strategies design for prevention of precancerous processes and cervical cancer associated with HPV.

  • Open Access

    Changes in gastric microbiota associated with Helicobacter pylori eradication therapy in a patient with gastritis

    by E. V. Voropaev, O. V. Osipkina, A. A. Kovalev, A. S. Shaforost, A. A. Ziatskov, A. V. Voropaeva, N. I. Shevchenko, Yu. A. Nazarchuk, I. O. Stoma

    Objective. To evaluate dynamic changes in the gastric microbiota against the background of Helicobacter pylori eradication therapy in a patient with gastritis using the method of high-throughput sequencing based on the analysis of variable regions of the 16s rRNA gene.Materials and methods. The patient (male, 57 years old) with chronic associated Helicobacter pylori (H. pylori) moderately severe and moderately active gastritis of the antrum and body of the stomach without atrophy and metaplasia. There is no primary resistance of H. pylori to clarithromycin according to polymerase chain reaction results.Next generation sequencing method based on the analysis of variable regions of the 16S rRNA gene was used to study the gastric microbiota. H. pylori eradication was performed according to the following scheme: amoxicillin, clarithromycin, omeprazole. The study included gastric mucosa (GM) biopsy samples obtained from unchanged tissue (N) and pathologically altered tissue (P) at different stages of treatment during 12 months. Taxonomic identification of reads was performed using the DRAGEN Metagenomics software package (Kraken2 algorithm).Results. Negative dynamics of alpha-diversity of gastric microbiome (by 5.8 times) was noted in the patient without treatment when assessing the unchanged tissue of the stomach. When antibiotic therapy was used, an increase in alpha-diversity of the gastric microbiota by more than eight times was noted.Conclusion. Analysis of the data of taxonomic diversity of gastric microbiota in morphologically different samples of the gastric microbiota at different stages of therapy indicates positive changes in the dynamic composition of the gastric microbiota in the course of treatment, which is confirmed by a decrease in the relative representation of H. pylori. When using therapy based only on proton pump inhibitors, the number of H. pylori is not significantly reduced. The dynamics of alpha-diversity of gastric microbiota is related to the morphological state of the tissue, and without the use of therapy has a significant and rather rapid tendency to a significant decrease (2-fold in less than two months). It is possible to achieve reduction of H. pylori to minimal amounts using standard first-line eradication therapy based on clarithromycin, but complete eradication does not occur.

  • Open Access

    Determination of Helicobacter pylori primary resistance to levofloxacin in gastric mucosal biopsy samples using real-time polymerase chain reaction

    by A. V. Voropaeva, N. I. Shevchenko

    Objective. To study the primary resistance of Helicobacter pylori (H. pylori) to levofloxacin in residents of Gomel region by real-time polymerase chain reaction (RT PCR).Materials and methods. The study included 170 patients diagnosed with gastritis and duodenitis, K29, median age - years (25% and 75% 37 and 61 years). According to the questionnaire data of the patients, eradication therapy with levofloxacin was not performed for them. To determine the resistance of H. pylori to levofloxacin we used RT PCR. Results. Out of 170 DNA samples analyzed, 8 samples had doubtful results and according to the methodology for recording the results are subject to rearrangement from the DNA isolation stage. The remaining 162 samples were positive for the β-actin gene (internal control sample ICS) and were taken into account in further analysis (Ct, CY5 19.6-27.4). 16sRNA gene DNA (Ct, ROX 19.5-30.04), indicative of bacterial infection, was confirmed in 152 samples (93.8%). DNA of the gyrA gene (point mutations A259T, T261C, G261A, G271A, G271T and A272G) was detected in 19 of 152 DNA samples, and H. pylori resistance to levofloxacin was 12.5 %, (Ct, Hex 23.2-30.7). The positive control samples had characteristic curve growth on the corresponding detection channels, while the negative samples showed no curve growth.Conclusion. Primary resistance of H. pylori to levofloxacin in residents of Gomel region amounted to 12.5%. Mutations of gyrA gene are the most sensitive marker for predicting successful eradication when using fluoroquinolones, in particular levofloxacin. RT PCR is a reliable method of mutation detection and allows simultaneous detection of H. pylori DNA and resistance to levofloxacin, which significantly reduces the study time.

  • Open Access

    Experience of Klebsiella pneumoniae genome sequencing using the short read method on the Illumina platform

    by A. S. Shaforost, A. A. Ziatskov, E. V. Voropaev, O. V. Osipkina, A. V. Voropaeva, N. A. Bonda, I. O. Stoma

    Objective. To review the main stages of Klebsiella pneumoniae genome sequencing using the Illumina short-read method and describe the peculiarities of sample library preparation and analysis of the obtained data.Materials and methods. Deoxyribonucleic acid (DNA) for high-throughput sequencing was isolated from Klebsiella pneumoniae cultures. Sample preparation was performed according to the manufacturer’s instructions for the Nextera XT DNA Library Prep kit. Sequencing was performed on an Illumina MiSeq platform using a 2x151 cartridge. Genome assembly to the contigs was performed using the SPAdes Genome Assembler application on the Illumina BaseSpace Sequence Hub service and a set of programs in a Linux environment. The quality of genome assembly was assessed using the QUAST service.Results. Genome sequencing of K. pneumoniae culture samples was performed, followed by an evaluation of the quality of the launch, assembly of the genome, and determination of its main parameters.Conclusion. The main steps of K. pneumoniae genome sequencing have been considered using the short-read method on the Illumina platform. The main parameters for assessing the quality of sample preparation, launch and genome assembly are described.

  • Open Access

    Determination of Helicobacter pylori resistance to clarithromycin in biopsy samples of gastric mucosa using TaqMan® MGB probes

    by A. V. Voropaeva, A. D. Borsuk, N. I. Shevchenko, S. M. Martynenko

    Objective. To study primary resistance of H. pylori to clarithromycin in residents of Gomel region by real-time polymerase chain reaction (PCR RT) using TaqMan® MGB probes.Materials and methods. The study included 184 patients diagnosed with gastritis and duodenitis, K29, median age 48.5 years (25% and 75% were 37 and 61 years old). According to the patients’ questionnaires, no clarithromycin-based eradication therapy was administered. To determine the resistance of H. pylori to clarithromycin, a PCR RV method using TagMan® MGB probes was used.Results. All 184 tested DNA samples were positive for the Rnase P gene (ICS) and were considered in further analysis (Ct, HEX 20.20-34.14). DNA from the cagH gene (Ct, FAM 21.26-33.04), indicating infection with the bacterium, was confirmed in 152 samples (82.6%). DNA from the 23SrRNA gene (point mutations A2142G and A2143G) was detected in 16 of 152 DNA samples 10.5 % (Ct, Hex 20.24-31.17). The positive control samples had characteristic curve growth in the corresponding detection channels; no curve growth was observed in the negative samples.Conclusion. The primary resistance of H. pylori to clarithromycin in the residents of Gomel region was 10.5%, and the use of triple first-line eradication therapy, including PPIs, amoxicillin and clarithromycin, as empirical in this region is consistent with the Maastricht III-VI recommendations and Decree of the Ministry of Health of the Republic of Belarus of 01.06.2017 № 54: clinical protocol “Diagnosis and treatment of patients with digestive diseases.” The use of PCR RT using TaqMan® MGB probes is justified to determine the resistance of H. pylori to clarithromycin, to prescribe individualized treatment and to evaluate the effectiveness of eradication regimens.